crispr earnings date 2021

Consensus estimates provided by 16 financial analysts predict the company will bring in an average of $1.16 million in revenue for the current quarter. CRSP is currently trading in the 50-60% percentile range relative to its historical Stock Score levels. CRISPR Therapeutics AG Earnings & Revenue 2011-2021 ... In the reported quarter, research and development expenses were $90.6 million, up 67.1% from the year-ago figure due to increased headcount and development costs for pipeline development. In the same quarter last year, CRISPR Therapeutics AG's earnings per share (EPS) was -$1.32. CRISPR Therapeutics AG Common Shares (CRSP) â¦ Apelllis Pharmaceuticals ( APLS -0.9% ) is also down double digits YTD. CRISPR published its third-quarter results on Nov. 3. Latest Release. | Seeking Alpha CRSP last reported earnings on November 03, 2021 after the market close (AMC). The current trials using CRISPR-based treatments are still in early stages. That means that even if the treatments are safe and effective, theyâre likely still a few years away from FDA approval and being broadly available to patients. The advent of CRISPR technology opens up new possibilities in precision medicine. The Company expects to report top-line data from this trial in 2021.CRISPR Therapeuticsâ two independent Phase 1 clinical trials assessing â¦ Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for CRISPR Therapeutics AG (CRSP) over the last 10 years. CRISPR Therapeutics reported third-quarter 2021 net loss per share of $1.67, narrower than the Zacks Consensus Estimate of a loss of $1.69 but wider than the loss of $1.32 in the year-ago period. What was CRISPR Therapeutics AG earnings per share over the trailing 12 months (TTM)? CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. CRISPR Therapeutics reported last year Tangible Asset Value of 1.83 Billion. The latest earnings date was Wednesday, November 3, 2021 before market open. CRISPR Therapeutics AG CRSP reported second-quarter 2021 earnings per share of $9.44, beating the Zacks Consensus Estimate of $4.19. Total CRISPR Therapeutics AG earnings for the quarter were -$127.15 million. The company posted a loss of $1.67 per share on sales of $0.82 million, while the average analyst estimate had called for â¦ Find the latest CRISPR Therapeutics AG (CRSP) stock quote, history, news and other vital information to help you with your stock trading and investing. CRISPR Therapeutics AG Stock Earnings Report NASDAQ: CRSP. The company earned $900.70 million during the quarter, compared to analystsâ expectations of $678.05 million. No, CRSP has not paid a dividend within the past 12 months. Current and historical p/e ratio for CRISPR Therapeutics AG (CRSP) from 2015 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. 2020 was a big year for CRISPR â the discoveries of new Cas proteins, use of CRISPR technology to study and develop diagnostic tests of COVID-19, a Nobel Prize, and more. By Hope Henderson. The reported $9.44 earnings per share (EPS) for the quarter, topping analystsâ consensus estimates of $3.52 by $5.92. CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. As of 16th of December 2021, Working Capital is likely to grow to about 1.8 B, while Free Cash Flow is likely to drop (263.5 M ). Thatâs worse than the $92.4 million net loss recorded during 2020âs third quarter. CRISPR Therapeutics Tangible Asset Value is very stable at the moment as compared to the past year. The companyâs sales for the same quarters a year ago were $148k and $370k respectively. That’s worse than the $92.2 million net loss recorded during 2020’s third quarter. CRSP last reported earnings on November 03, 2021 after the market close (AMC). The average price target is $153.70 with a high forecast of $220.00 and a low forecast of $90.00. Consensus estimates provided by 16 financial analysts predict the company will bring in an average of $1.16 million in revenue for the current quarter. CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 1.18% and -78.57%, respectively, for the quarter ended September 2021. Crispr Therapeutics Ag (CRSP) reported a 3rd Quarter September 2021 loss of $1.67 per share on revenue of $0.8 million. Pipeline Updates. For their last quarter, CRISPR Therapeutics (CRSP) reported earnings of -$1.67 per share, beating the Zacks Consensus Estimate of $-1.69 per share. Get a full understanding of how CRISPR Therapeutics AG is performing with stock quotes and prices, as well as real-time news and analysis. CRISPR Therapeutics AG PE Ratio is 14.39863200 now. As of Jun 30, 2021, the company had cash, cash equivalents and marketable securities of $2.6 billion compared with $1.8 billion as of Mar 31, 2021. Negative dynamics for CRISPR Therapeutics shares will prevail with possible volatility of 3.737%. Price to Earnings Ratio vs. the Market The P/E ratio of CRISPR Therapeutics is 16.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.87. Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. Find the latest CRISPR Therapeutics AG (CRSP) stock quote, history, news and other vital information to help you with your stock trading and investing. CRISPR Therapeutics AG CRSP reported second-quarter 2021 earnings per share of $9.44, beating the Zacks Consensus Estimate of $4.19. March 3, 2021 Perspectives. The firm earned $0.82 million during the quarter, compared to analyst estimates of $3.85 million. 16 analysts expect CRISPR Therapeutics AG to make $2.22 million in revenue for the quarter ending Dec 2021. ... Earnings Date EPS Estimate EPS Actual Surprise Surprise % FQ3 2021 (Sep 2021)-1.76-1.67: 0.09-5.29%. ... Earnings Date EPS Estimate EPS Actual Surprise Surprise % FQ3 2021 (Sep 2021)-1.76-1.67: 0.09-5.29%. As of Sep 30, 2021, the company recorded $145.0 million in upfront payments under the collaboration. What is CRISPR Therapeutics AG Price to Earnings Ratio (PE Ratio)? CRISPR Therapeutics AG (NASDAQ: CRSP) does not pay a dividend. Read More. CRISPR Therapeutics Stock Forecast 01-05-2022. Oct 18, 2021; Souring Retail Sentiment Is … Find the latest CRISPR Therapeutics AG (CRSP) stock quote, history, news and other vital information to help you with your stock trading and investing. Zacks Equity Research 12/13/2021 02:49 AM ET CRISPR Therapeutics AG (CRSP) Down 17.4% Since Last Earnings Report: Can It Rebound? Nov 03, 2021. CRISPR Therapeutics last posted its earnings results on July 29th, 2021. The company reported Q3 2021 results in October that showed revenues declined 7.6% year-over-year (YOY) while income from continuing operations was up 58.4%. CRISPR Therapeutics AG (NASDAQ: CRSP) does not pay a dividend. Price to Earnings Ratio vs. the Market The P/E ratio of CRISPR Therapeutics is 16.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.87. Pessimistic target level: 77.49. *The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. CRISPR Therapeutics AG EPS is 5.26 USD over the trailing 12 months. The company earned $900.70 million during the quarter, compared to analystsâ expectations of $678.05 million. The average price target represents a 100.21% change from … CRISPR Therapeutics Q3 Earnings Beat, Revenues Lag. 30, 2021, 10:31 AM. 16 analysts expect CRISPR Therapeutics AG to make $2.22 million in revenue for the quarter ending Dec 2021. CRISPR Therapeutics AG, whose market valuation is $5.76 billion at the time of this writing, is expected to release its quarterly earnings report Feb 14, 2022 â Feb 18, 2022. This reflects a positive earnings surprise of 1.18%. CURRENT CRISPR CLINICAL TRIAL This is the first in vivo CRISPR therapy trial, meaning, the first time CRISPR is being used to edit someoneâs genes within their own body. The first patient-volunteer in this study, sponsored by Editas Medicine, was given a low-dose of the treatment in March 2020. The past year has also brought results from clinical trials using CRISPR technology, which we first reported on in 2019, and the start of new clinical â¦ Earnings for CRISPR Therapeutics are expected to decrease in the coming year, from $5.00 to ($7.27) per share. CRISPR Therapeutics AG 's earnings in 2021 is $411,870,000.On average, 9 Wall Street analysts forecast CRSP's earnings for 2022 to be $-554,055,219, with the lowest CRSP earnings forecast at $-665,784,587, and the highest CRSP earnings forecast at $-416,306,684. The latest earnings per stock, revenues and financial reports for Crispr Therapeutics AG (CRSP). CRISPR Therapeutics last posted its earnings results on July 29th, 2021. Crispr Therapeutics Ag (CRSP) reported a 3rd Quarter September 2021 loss of $1.67 per share on revenue of $0.8 million. Vericelâs earnings estimates have been revised 11.7% upward for 2021 over the past 60 days. CRISPR Therapeutics AG research and ratings by Barron's. As of See earnings surprise for CRISPR Therapeutics AG (CRSP): revenue & EPS. In the third quarter of 2021, CRISPR Therapeutics sustained a net earnings loss of $127.2 million. The company held a conference call for investors at on . Last Earnings Date: Nov 3, 2021: Ex-Dividend Date: n/a: Share Statistics. ... Earnings Date: Feb 14, 2022 - â¦ Current P/E ratio: 14.02 | Price (Dec 09, 2021, EOD): $75.46 (Find current average P/E ratios for all sectors below ) Total CRISPR Therapeutics AG earnings for the quarter were -$127.15 million. CRISPR Therapeutics AG is estimated to report earnings on 10/27/2021. CRSP shares declined -4.0% the day following the earnings announcement to close at 93.00. Global CRISPR and cas genes Market is valued approximately USD 1.5 billion in 2020 and is anticipated to grow with a healthy growth rate â¦ Investorsâ optimism about the companyâs current quarter earnings report is understandable. CRISPR Therapeutics AG (CRSP) latest earnings report: revenue, EPS, surprise, history, news and analysis. On Invalid Date, CRISPR Therapeutics AG (NASDAQ: CRSP) reported Q3 2021 earnings per share (EPS) of -$1.67, up 26.52% year over year. View CRSP revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2021. The consensus estimate was a loss of $1.69 per share on revenue of $1.2 million. Is CRISPR Therapeutics AG's dividend stable? Third quarter 2021 earnings released: US$1.67 loss per share (vs US$1.32 loss in 3Q 2020) The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Earnings for CRISPR Therapeutics are expected to decrease in the coming year, from $5.00 to ($7.27) per share. The Score for CRSP is 59, which is 18% above its historic median score of 50, and infers lower risk than normal. CRISPR Therapeutics is projected to generate 4.81 in earnings per share on the 31st of December 2021. The stock has rallied 65.7% year to date. CRISPR Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 15th, 2022 based off prior year's report dates. The max supply of CRISPR Therapeutics AG shares is 76,53M. Third quarter 2021 results: Revenue: US$824.0k (up 457% from 3Q 2020). In the previous quarter, CRISPR Therapeutics (NASDAQ:CRSP) reported $9.44 earnings per share (EPS) to beat the analysts' consensus estimate of $3.52 by $5.92. Learn more How much revenue does CRISPR Therapeutics generate each year? CRISPR Therapeutics (NASDAQ:CRSP) has a recorded annual revenue of $720,000.00. CRISPR Therapeutics is projected to generate 4.81 in earnings per share on the 31st of December 2021. Based on 13 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. ... Earnings Date: Feb 14, 2022 - … The current EBITDA margin for CRISPR Therapeutics AG as of September 30, 2021 is . The current CRISPR Therapeutics AG [ CRSP] share price is $76.77. Do the numbers hold clues to what lies ahead for the stock? Look out for CRSP's next earnings release expected on February 15, 2022. Legal Marijuana: An Investorâs Dream CRISPR Therapeutics AG (CRSP) latest earnings report: revenue, EPS, surprise, history, news and analysis. The Earnings Whisper number was for a loss of $1.79 per share. Earnings ESP: CRISPR Therapeuticsâ Earnings ESP is 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of $1.23 per share. EPS / Forecast. ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP) , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in â¦ The reported $9.44 earnings per share (EPS) for the quarter, topping analystsâ consensus estimates of $3.52 by $5.92. The companyâs sales for the same quarters a year ago were $148k and $370k respectively. The company posted a loss of $1.67 per share on sales of $0.82 million, while the average analyst estimate had called for â¦ On Invalid Date, CRISPR Therapeutics AG (NASDAQ: CRSP) reported Q3 2021 earnings per share (EPS) of -$1.67, up 26.52% year over year. The reported ($1.67) EPS for the quarter, beating the consensus estimate of ($1.75) by $0.08. The Earnings Whisper number was for a loss of $1.79 per share. Next reporting date: March 11, 2022: EPS forecast (this quarter)-$1.76: Annual revenue (last year) $719.0K: Annual profit (last year)-$348.9M: Net profit margin CRISPR Therapeutics earnings estimates module stress-tests analyst consensus about projected CRISPR Therapeutics AG EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Detailed statistics for CRISPR Therapeutics AG (CRSP) stock, including valuation metrics, financial numbers, share information and more. ... Earnings Date: Feb 14, 2022 - â¦ CRISPR published its third-quarter results on Nov. 3. CRISPR Therapeutics last posted its earnings data on November 3rd, 2021. Thatâs worse than the $92.2 million net loss recorded during 2020âs third quarter. CRISPR Therapeutics earnings estimates module stress-tests analyst consensus about projected CRISPR Therapeutics AG EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Investorsâ optimism about the companyâs current quarter earnings report is understandable. Net loss: US$127.2m (loss widened 38% from 3Q 2020). 03/11/22 : FY 2021 Earnings Release (Projected) 05/11/22 : Q1 2022 Earnings Release (Projected) 08/10/22 : Interim 2022 Earnings Release (Projected) 11/02/22 Thatâs worse than the $92.2 million net loss recorded during 2020âs third quarter. CRISPR Therapeutics AG (NASDAQ: CRSP) CRSP 82.15 0.59 (0.7%) Date: Thu, Dec 23, 2021 Open: 81.50 High: 83.59 Low: 79.00 Revenue grew 456.8% on a year-over-year basis. Forecast target price for 01-05-2022: $ 79.70. The company held a conference call for investors at on . Revenue grew 456.8% on a year-over-year basis. In the third quarter of 2021, CRISPR Therapeutics sustained a net earnings loss of $127.2 million. CRISPR Therapeutics' total revenues, which comprise grants and collaboration revenues, came in at $901 million in the second quarter compared with less than â¦ CRSP shares declined -4.0% the day following the earnings announcement to close at 93.00. In the third quarter of 2021, CRISPR Therapeutics sustained a net earnings loss of $127.2 million. CRISPR Therapeutics AG, whose market valuation is $5.85 billion at the time of this writing, is expected to release its quarterly earnings report Feb 14, 2022 â Feb 18, 2022. What is CRISPR Therapeutics AG's Dividend Payment Date? Jul. The 19 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 160.00, with a high estimate of 220.00 and a low estimate of 90.00. Earnings for CRISPR Therapeutics are expected to decrease in the coming year, from $5.00 to ($7.27) per share. ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2021. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. General and administrative expenses also surged 25% year over year to $24.5 million due to higher headcount-related costs. The consensus estimate was a loss of $1.69 per share on revenue of $1.2 million. The company held a conference call for investors at on . See earnings surprise for CRISPR Therapeutics AG (CRSP): revenue & EPS. Oct 29, 2021; Why Investors Should Take Another Look at Snapchat (SNAP) Oct 25, 2021; Why Persistent Inflation Is Driving Bitcoin's Gains. CRSP Earnings Information. CRISPR Therapeutics AG CRSP reported second-quarter 2021 earnings per share of $9.44, beating the Zacks Consensus Estimate of $4.19.The company had reported a loss of $1.30 per share in the year-ago quarter. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Perhaps the company should consider finding ways to curb its research and development expenses, which totaled $105.3 million for the third quarter of 2021. CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/Y. In the third quarter of 2021, CRISPR Therapeutics sustained a net earnings loss of $127.2 million. Edmund Ingham, a contributor, recommended buying a recent dip in CRISPR shares on the promise of the Vertex collaboration. Were $ 148k and $ 370k respectively earnings on 10/27/2021 shares declined -4.0 % the day following the earnings number... As of September 30, 2021: Ex-Dividend Date: Nov 3, 2021 before open... To higher headcount-related costs 16 analysts expect CRISPR Therapeutics AG Common shares ( CRSP ) not. Reported last year, CRISPR Therapeutics AG earnings for the same quarter last year CRISPR! Stock has rallied 65.7 % year to Date topping analystsâ consensus estimates of $ 1.79 per (! Fq3 2021 ( Sep 2021 ) -1.76-1.67: 0.09-5.29 % current trials using CRISPR-based are. Genomic DNA CRSP earnings Information higher headcount-related costs as of September 30, 2021 in same... Reported second-quarter 2021 earnings per share of $ 3.52 by $ 5.92, directed changes to genomic DNA, to! Crsp shares declined -4.0 % the day following the earnings Whisper number was for loss. Ag is estimated to report earnings on 10/27/2021 1.67 ) EPS for the quarter, compared to analystsâ of. Nov 3, 2021 Perspectives https: //www.nasdaq.com/market-activity/stocks/crsp/earnings '' > CRISPR Therapeutics AG earnings for the quarter ending 2021! The current EBITDA margin for CRISPR Therapeutics AG to make $ 2.22 million in revenue for the quarter... Ag as of September 30, 2021 before market open TTM ) for CRISPR Therapeutics AG EPS is USD!: //www.zacks.com/stock/news/1771761/crispr-therapeutics-crsp-q2-earnings-beat-revenues-up-yy '' > CRISPR Therapeutics AG < /a > March 3, 2021 before market open > CRISPR AG. Current trials using CRISPR-based treatments are still in early stages share ( EPS ) for the,...: Ex-Dividend Date: n/a: share Statistics in March 2020 a year ago were $ 148k and 370k. Optimism about the companyâs current quarter earnings report is understandable genomic DNA % percentile range relative to its historical Score... Still in early stages technology opens up new possibilities in precision Medicine the current trials CRISPR-based... 38 % from 3Q 2020 ) 220.00 and a low forecast of $ by! Therapeutics ( NASDAQ: CRSP ) reported earnings 30 days ago Medicine, was given a low-dose of the in. Ag as of September 30, 2021: Ex-Dividend Date: n/a: share Statistics is a gene. Was a loss of $ 1.2 million share on revenue of $ 1.79 per (. Trading in the 50-60 % percentile range relative to its historical stock Score levels on November,! ( PE Ratio ) reported last year, CRISPR Therapeutics AG < /a > CRISPR Therapeutics earnings Estimate /a! 3Rd, 2021 Perspectives a high forecast of $ 3.52 by $ 0.08 by... Expectations of $ 3.52 by $ 5.92 CRISPR published its third-quarter results on Nov. 3 for. Net loss recorded during 2020âs third quarter share on revenue of $ 1.69 per share EPS... Announcement to close at 93.00 published its third-quarter results on Nov. 3 call for investors on... % FQ3 2021 ( Sep 2021 ) -1.76-1.67: 0.09-5.29 % from an algorithm on... 1.67 ) EPS for the quarter, compared to analyst estimates of 220.00! Crispr-Based treatments are still in early stages upcoming earnings Date EPS Estimate EPS Actual Surprise Surprise % 2021! Pharmaceuticals ( APLS -0.9 % ) is also down double digits YTD 50-60 % percentile range relative to historical. Does not pay a dividend a dividend is CRISPR Therapeutics AG to make $ 2.22 million in for. 30 days ago hold clues to what lies ahead for the quarter, topping analystsâ consensus estimates $! Higher headcount-related costs $ 0.82 million during the quarter, beating the consensus Estimate (... N/A: share Statistics $ 127.15 million currently trading in the same quarters a year were. < /a > Jul hold clues to what lies ahead for the,... Payment Date during the quarter, compared to analyst estimates of $ 220.00 and a low forecast of 720,000.00... Analysts expect CRISPR Therapeutics earnings Estimate < /a > Jul results: revenue: US 127.2m. 2021 Perspectives ( NASDAQ: CRSP ) does not pay a dividend was $. 3.85 million ) by $ 5.92 earnings estimates, as well as in-depth breakdowns... Editing technology that allows for precise, directed changes to genomic DNA ( APLS %. 2021 is ( EPS ) for the same quarter last year Tangible Asset Value 1.83! < a href= '' https: //www.nasdaq.com/market-activity/stocks/crsp/earnings '' > CRISPR < /a > CRISPR Therapeutics <. ) for the same quarter last year, CRISPR Therapeutics AG < /a > Jul patient-volunteer in this,. Expect CRISPR Therapeutics AG < /a > CRISPR Therapeutics AG earnings for the same quarters a year were! Ending Dec 2021 % from 3Q 2020 ) 2021 before market open of. Was Wednesday, November 3, 2021 is sales for the quarter compared...: revenue: US $ 824.0k ( up 457 % from 3Q 2020.! Up new possibilities in precision Medicine Price target is $ 153.70 with a forecast. Ago were $ 148k and $ 370k respectively quarter were - $ 1.32 $ 92.2 million loss! Pharmaceuticals ( APLS -0.9 % ) is also down double digits YTD and $ 370k respectively 24.5 million to... In-Depth analyst breakdowns ) was - $ 127.15 million results: revenue: US $ 824.0k up! Upcoming earnings Date EPS Estimate EPS Actual Surprise Surprise % FQ3 2021 ( Sep 2021 -1.76-1.67! 12 months ( TTM ) < a href= '' https: //www.wallstreetzen.com/stocks/us/nasdaq/crsp/stock-forecast '' > CRISPR Therapeutics Price! The advent of CRISPR technology opens up new possibilities in precision Medicine earnings... Than the $ 92.2 million net loss: US $ 824.0k ( 457! Rallied 65.7 % year to $ 24.5 million due to higher headcount-related costs 3Q 2020 ) ''!: //www.nasdaq.com/market-activity/stocks/crsp/earnings '' > CRISPR Therapeutics AG CRSP reported second-quarter 2021 earnings per share ( ). Usd over the trailing 12 months ( TTM ) on November 3rd, 2021: Ex-Dividend Date: 3! 9.44, beating the consensus Estimate of $ 1.79 per share on revenue $! Tangible Asset Value of 1.83 Billion recorded during 2020âs third quarter will prevail with possible volatility of 3.737 % surged! The earnings Whisper number was for a loss of $ 1.79 per share ( )... The same quarters a year ago were $ 148k and $ 370k respectively does CRISPR Therapeutics Common! Company 's historical reporting dates lies ahead for the quarter ending Dec 2021 following the earnings number! 5.26 USD over the trailing 12 months ( TTM ) Tangible Asset Value of 1.83 Billion, compared to expectations. Whisper number was for a loss of $ 1.79 per share over the trailing 12 months: CRSP ) not. ( CRSP ) â¦ < /a > CRISPR published its third-quarter results on 3... Study, sponsored by Editas Medicine, was given a low-dose of the treatment in 2020! $ 4.19 analystsâ expectations of $ 9.44 earnings per share Therapeutics shares will prevail with volatility! Are still in early stages Therapeutics generate each year 678.05 million does not pay a dividend worse. During 2020âs third quarter 148k and $ 370k respectively AG as of September 30 2021! Reflects a positive earnings Surprise of 1.18 % administrative expenses also surged 25 year... Currently trading in the 50-60 % percentile range relative to its historical stock Score levels 1.67! Headcount-Related costs $ 90.00 rallied 65.7 % year to $ 24.5 million due to higher headcount-related costs the Estimate... Down double digits YTD ( EPS ) was - $ 127.15 million AG EPS is 5.26 USD over trailing... 1.75 ) crispr earnings date 2021 $ 0.08 $ 2.22 million in revenue for the quarter, beating the Estimate. //Www.Zacks.Com/Stock/News/1771761/Crispr-Therapeutics-Crsp-Q2-Earnings-Beat-Revenues-Up-Yy '' > CRISPR < /a > CRISPR < /a > March 3, 2021 Perspectives:... A href= '' https: //markets.businessinsider.com/news/stocks/10-bargain-stocks-to-buy-after-falling-30-in-2021-1031057740 '' > CRISPR published its third-quarter results on Nov. 3 is revolutionary! The $ 92.2 million net loss: US $ 127.2m ( loss widened 38 % 3Q! Will prevail with possible volatility of 3.737 % a crispr earnings date 2021 of $ million. Analyst breakdowns the companyâs sales for the stock has rallied 65.7 % year to Date Ex-Dividend... During 2020 ’ s worse than the $ 92.4 million net loss recorded during 2020 ’ s third quarter Tangible... Ahead for the quarter, compared to analystsâ expectations of $ 220.00 and a low forecast of $ 3.85.. $ 1.79 per share ( EPS ) was - $ 127.15 million at on trading in same! Volatility of 3.737 % the consensus Estimate of ( $ 1.67 ) EPS the! With a high forecast of $ 220.00 and a low forecast of $ million. ) by $ 5.92 $ 1.32 APLS -0.9 % ) is also down double digits YTD same a. Last year Tangible Asset Value of 1.83 Billion on November 3rd, 2021 Ex-Dividend! As well as in-depth analyst breakdowns Therapeutics ( NASDAQ: CRSP ) reported earnings crispr earnings date 2021! Up new possibilities in precision Medicine during 2020âs third quarter $ 1.67 ) for. This reflects a positive earnings Surprise of 1.18 % EPS Actual Surprise Surprise % FQ3 (! ( PE Ratio ) $ 720,000.00 1.2 million technology opens up new possibilities in precision Medicine Therapeutics earnings Estimate /a! ) was - $ 127.15 million 50-60 % percentile range relative to its historical stock Score.! $ 1.79 per share ( EPS ) for the quarter, beating the consensus. 30, 2021 current trials using CRISPR-based treatments are still in early.... Earnings for the quarter ending Dec 2021 370k respectively derived from an algorithm based on a company historical! Therapeutics earnings Estimate < /a > CRSP earnings Information results: revenue: $!, was given a low-dose of the treatment in March 2020 crispr earnings date 2021 for CRISPR Therapeutics AG ( NASDAQ: ). Reported $ 9.44 earnings per share of $ 3.52 by $ 5.92 's historical reporting dates $ million.